NASDAQ:TECH - BIO-TECHNE Stock Price, Forecast & News

BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."

BIO-TECHNE declared a quarterly dividend on Tuesday, February 4th. Shareholders of record on Friday, February 14th will be paid a dividend of $0.32 per share on Friday, February 28th. This represents a $1.28 dividend on an annualized basis and a yield of 0.61%. The ex-dividend date is Thursday, February 13th. View BIO-TECHNE's Dividend History.

BIO-TECHNE Corp (NASDAQ:TECH) announced its quarterly earnings results on Tuesday, February, 4th. The biotechnology company reported $1.08 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $1.13 by $0.05. The biotechnology company earned $184.93 million during the quarter, compared to analysts' expectations of $191.34 million. BIO-TECHNE had a return on equity of 12.45% and a net margin of 26.20%. The business's revenue was up 6.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.06 EPS. View BIO-TECHNE's Earnings History.

BIO-TECHNE is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for BIO-TECHNE.

8 brokerages have issued 1 year price targets for BIO-TECHNE's shares. Their forecasts range from $225.00 to $270.00. On average, they expect BIO-TECHNE's share price to reach $238.33 in the next year. This suggests a possible upside of 14.3% from the stock's current price. View Analyst Price Targets for BIO-TECHNE.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIO-TECHNE.

Media coverage about TECH stock has been trending very negative this week, according to InfoTrie. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. BIO-TECHNE earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for BIO-TECHNE.

BIO-TECHNE saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 485,700 shares, an increase of 16.2% from the January 15th total of 418,000 shares. Based on an average daily volume of 124,100 shares, the short-interest ratio is currently 3.9 days. Currently, 1.3% of the company's shares are sold short. View BIO-TECHNE's Current Options Chain.

Some companies that are related to BIO-TECHNE include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), Charles River Laboratories Intl. (CRL), Bruker (BRKR), Cambrex (CBM), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other BIO-TECHNE investors own include Paychex (PAYX), AbbVie (ABBV), Gilead Sciences (GILD), Amgen (AMGN), NVIDIA (NVDA), General Electric (GE), Global Medical REIT (GMRE), Crispr Therapeutics (CRSP), Cisco Systems (CSCO) and Ionis Pharmaceuticals (IONS).

BIO-TECHNE's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Mairs & Power INC (2.62%), Jackson Square Partners LLC (2.56%), State Street Corp (2.33%), Champlain Investment Partners LLC (2.26%), Massachusetts Financial Services Co. MA (2.10%) and Fred Alger Management LLC (2.10%). Company insiders that own BIO-TECHNE stock include Brenda S Furlow, Charles A Dinarello, Charles R Kummeth, Harold J Wiens, James Hippel, John L Higgins, Norman David Eansor, Robert V Baumgartner and Roeland Nusse. View Institutional Ownership Trends for BIO-TECHNE.

TECH stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, First Trust Advisors LP, Renaissance Technologies LLC, Schroder Investment Management Group, AQR Capital Management LLC, Mairs & Power INC, Royce & Associates LP and Lord Abbett & CO. LLC. Company insiders that have sold BIO-TECHNE company stock in the last year include Brenda S Furlow, Charles R Kummeth, Harold J Wiens, James Hippel, John L Higgins, Norman David Eansor and Roeland Nusse. View Insider Buying and Selling for BIO-TECHNE.

TECH stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Jackson Square Partners LLC, Candriam Luxembourg S.C.A., Candriam Luxembourg S.C.A., Champlain Investment Partners LLC, Thrivent Financial for Lutherans, UBS Group AG and Cambridge Investment Research Advisors Inc.. Company insiders that have bought BIO-TECHNE stock in the last two years include Charles R Kummeth and Robert V Baumgartner. View Insider Buying and Selling for BIO-TECHNE.

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TECH stock can currently be purchased for approximately $208.53.

BIO-TECHNE has a market capitalization of $8.00 billion and generates $714.01 million in revenue each year. The biotechnology company earns $96.07 million in net income (profit) each year or $3.80 on an earnings per share basis. BIO-TECHNE employs 2,250 workers across the globe.View Additional Information About BIO-TECHNE.

The official website for BIO-TECHNE is http://www.techne-corp.com/.

BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]